You've heard the term "digital therapeutics" thrown around at conferences and in vendor pitches. Maybe you've seen reSET mentioned in clinical literature or heard that some programs are prescribing apps. But if you're like most treatment center operators, you're not entirely sure what separates a digital therapeutic from a wellness app, what FDA clearance actually means, or how you'd bill for one.
Here's the reframe: digital therapeutics addiction treatment 2026 isn't about apps. It's about FDA-regulated prescription treatments, as clinically rigorous as a pharmaceutical, delivered through software. They require clinical trials, regulatory clearance, and physician oversight. They're not Headspace or Calm with a billing code.
This article breaks down what digital therapeutics actually are, what's cleared for substance use disorder, how reimbursement works in practice, and how forward-thinking programs are integrating them into care delivery.
What Makes a Digital Therapeutic Different from a Wellness App
The distinction matters for liability, reimbursement, and clinical credibility. A wellness app is software you download. A prescription digital therapeutic (PDT) is a medical device regulated by the FDA.
Digital therapeutics go through the same FDA clearance process as medical devices. That means De Novo classification for novel products or 510(k) clearance for products substantially equivalent to existing devices. It requires randomized controlled trials, clinical evidence of efficacy, and ongoing post-market surveillance.
The regulatory bar matters because it determines whether payers will cover the product, whether clinicians can prescribe it with legal clarity, and whether the product actually does what it claims. Wellness apps don't have to prove efficacy. Digital therapeutics do.
For behavioral health operators, this distinction affects how you integrate the tool, who oversees it, and whether you can get paid for it. If it's not FDA-cleared, it's not a prescription digital therapeutic, and your billing and compliance posture changes accordingly.
The SUD Digital Therapeutics Landscape: reSET, reSET-O, and What Happened After Pear
The most well-known FDA cleared digital therapeutics SUD products are reSET and reSET-O, both developed by Pear Therapeutics. reSET received FDA De Novo clearance in 2017 for substance use disorder (alcohol, cannabis, cocaine, stimulants). reSET-O followed in 2018 with 510(k) clearance for opioid use disorder, designed to be used alongside buprenorphine.
Both products deliver cognitive behavioral therapy modules through a mobile app. Patients complete lessons, track cravings and triggers, and receive contingency management rewards for engagement. Clinicians monitor progress through a dashboard and receive alerts for high-risk behavior.
Then Pear Therapeutics filed for bankruptcy in 2023. The products didn't disappear, but the company's collapse created uncertainty. Pear's assets were acquired, and as of 2026, the reSET addiction treatment app products remain available, though distribution and support structures have shifted.
For operators evaluating digital therapeutics, this history matters. The clinical evidence behind reSET and reSET-O is solid. The business model for DTx companies is still evolving. That tension affects vendor stability, product roadmaps, and long-term integration planning.
Beyond reSET, the pipeline includes other evidence-based tools like CBT4CBT (computer-based CBT for SUD) and CHESS Health's Connections platform. These aren't FDA-cleared PDTs, but they have peer-reviewed clinical evidence and are used in treatment settings. The distinction is regulatory, not necessarily clinical.
How Prescription Digital Therapeutics Work Inside a Treatment Program
In practice, integrating prescription digital therapeutics behavioral health programs requires clinical workflow changes, not just a software login.
A physician, nurse practitioner, or physician assistant prescribes the digital therapeutic, just like a medication. The patient receives a unique access code or prescription that unlocks the app. They complete modules on their own time, typically 10 to 20 minutes per session, multiple times per week.
Engagement data flows back to the treatment team. Clinicians see completion rates, self-reported cravings, and behavioral patterns. Some platforms integrate with EHRs. Most don't, which means manual data review or separate dashboards.
The value proposition is therapeutic contact outside of scheduled sessions. A patient in IOP might attend group three times per week. With a digital therapeutic, they're engaging with CBT content daily. That's additional therapeutic exposure without additional staffing costs.
For step-down patients transitioning from PHP to IOP or IOP to outpatient, digital CBT addiction treatment fills the gap. It's not a replacement for therapy. It's a bridge between sessions and a tool for extending evidence-based care into unstructured time.
The Reimbursement Reality: Why DTx Billing Remains Fragmented
Here's where the promise hits the pavement. Digital therapeutics reimbursement insurance coverage is inconsistent, and there's no universal CPT code for prescription digital therapeutics.
Some state Medicaid programs cover reSET and reSET-O. Commercial payers vary. Blue Cross Blue Shield medical policies outline technology evaluation criteria, but coverage decisions are made at the plan level, not nationally.
In practice, this means operators need to verify coverage on a per-patient, per-payer basis. Some programs build the cost into bundled rates. Others pursue separate reimbursement through miscellaneous codes or negotiate carve-outs with managed care contracts.
The lack of a dedicated CPT code is a structural barrier. Without it, billing is manual, denials are common, and revenue capture is inconsistent. This is a known issue in the DTx industry, and advocacy groups are pushing for coding clarity. But as of 2026, it's still a problem.
For operators, the workaround is to treat DTx as a clinical investment with indirect ROI. Better outcomes, lower readmission rates, and differentiated care models can justify the cost even if direct reimbursement is limited. If you're scaling a program and managing revenue cycle operations, DTx billing needs to be part of your payer contracting strategy from the start.
DTx as a Complement to Existing Levels of Care
The best use case for DTx addiction treatment program integration isn't replacement. It's augmentation.
IOP and PHP programs are using digital therapeutics to extend therapeutic contact hours without increasing group session frequency. A patient completes a reSET module at home, then discusses insights during their next group session. The app reinforces skills taught in therapy.
For programs with capacity constraints, DTx can increase patient throughput without adding clinical FTEs. You're delivering more therapeutic content per patient without more therapist hours.
Step-down transitions are another high-value use case. When a patient moves from residential to IOP, the drop in structure is abrupt. A digital therapeutic provides continuity. The patient is still engaging with evidence-based content daily, even if they're only attending group twice a week.
Some operators are also using DTx for alumni support and aftercare. Once a patient discharges, they can continue using the app as part of a continuing care plan. This extends the treatment relationship and provides ongoing engagement data that can trigger re-engagement outreach if usage drops.
The key is clinical integration, not bolt-on adoption. If the digital therapeutic isn't discussed in treatment planning, tracked in progress notes, and reinforced by the clinical team, engagement drops. Patients need to see it as part of their treatment plan, not a separate app they were told to download.
How to Evaluate a Digital Therapeutic for Your Program
If you're vetting vendors, here's what to ask.
Evidence base: Is the product FDA-cleared? What clinical trials support efficacy? For what population and diagnosis? Peer-reviewed publications matter more than white papers.
EHR integration: Does the platform integrate with your EHR, or will your team need to log into a separate dashboard? Data silos kill adoption.
Patient engagement data: What metrics does the platform track? Completion rates, time on task, self-reported outcomes? Can you export data for outcomes reporting and quality improvement?
Billing support: Does the vendor provide billing codes, payer policies, and reimbursement guidance? Will they help with prior authorizations? Or are you on your own?
Training and onboarding: What does clinical team training look like? How long does implementation take? What ongoing support is included?
Cost structure: Is it per patient, per month, or a flat license fee? Are there setup costs? What's the total cost per patient episode?
If you're opening or scaling a treatment center in a state with complex licensing requirements, like Florida or New York, understanding how digital therapeutics fit into your clinical model and payer contracts is part of your operational build.
What's Next for Digital Therapeutics in Addiction Treatment
The DTx space is maturing, but it's not mature. Regulatory clarity is improving. Reimbursement is still fragmented. Clinical evidence is strong for specific products, but adoption is slow.
For behavioral health operators, the opportunity is in early integration. Programs that figure out how to use digital therapeutics effectively, bill for them strategically, and integrate them into clinical workflows will have a differentiated care model and better outcomes data.
The risk is vendor instability and reimbursement uncertainty. That's why due diligence matters. You're not just buying software. You're integrating a regulated medical device into your treatment model.
As the market evolves, expect more FDA-cleared products, clearer billing codes, and broader payer coverage. But in 2026, the operators who move first are the ones who will define best practices.
Frequently Asked Questions
What is a prescription digital therapeutic?
A prescription digital therapeutic is an FDA-cleared software-based medical device that delivers evidence-based therapeutic interventions. It requires a prescription from a licensed clinician and is used to treat or manage a medical condition. Unlike wellness apps, PDTs go through clinical trials and regulatory review.
Is reSET still available?
Yes. Despite Pear Therapeutics' bankruptcy in 2023, reSET and reSET-O remain available. The products were acquired and continue to be distributed, though the vendor landscape has shifted. Operators should verify current availability and support structures with the product's current owner.
Can digital therapeutics replace therapy?
No. Digital therapeutics are designed to complement, not replace, traditional therapy. They extend therapeutic contact between sessions and reinforce evidence-based skills. They work best when integrated into a comprehensive treatment plan with clinical oversight.
How do I bill for digital therapeutics?
Billing for digital therapeutics is inconsistent. Some state Medicaid programs and commercial payers cover them, but there's no universal CPT code. Operators typically use miscellaneous codes, negotiate coverage in managed care contracts, or build costs into bundled rates. Verify coverage on a per-payer basis and work with your revenue cycle team to develop a billing strategy.
Ready to Integrate Digital Therapeutics into Your Program?
Digital therapeutics aren't a fad. They're FDA-regulated prescription treatments with clinical evidence. But integrating them requires more than a vendor contract. You need a clinical workflow, a billing strategy, and a team that understands how to use them effectively.
If you're building or scaling a behavioral health program and want to explore how digital therapeutics fit into your care model, we can help. From revenue cycle strategy to clinical integration, we work with operators who are building the next generation of addiction treatment.
Reach out to discuss how digital therapeutics can differentiate your program and improve patient outcomes.
